Bayer named Greg Babe president and CEO, replacing Dr. Attila Molnar, who is retiring in October. Babe joined Bayer in 1978 and most recently served as president and CEO of Bayer's MaterialScience LLC polymers and plastics business. Since 2002, he has presided over the implementation of the new Bayer organization in North America and the restructuring of its product portfolio, including more than 15 acquisitions and six divestitures. Over that period, Bayer's North American sales have increased around 50%.
Eisai promoted Lawrence Kristoff to field sales director, lymphoma, responsible for three district managers and 26 sales specialists focused on three oncology products. Kristoff was previously district manager, oncology. Eisai also promoted Mark Schwab from medical sales specialist to district manager in charge of Nashville.
InVentiv Health named Mark Rubin president of patient outcomes and Norman Stalsberg president of strategy and analytics. Rubin was previously CEO and co-founder of Adhereis, which inVentiv acquired in 2006 and which falls under the patient outcomes group, along with AWAC, The Franklin Group and The Therapeutics Institute. Stalsberg was previously president of inVentiv's CHS.